Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $10,813 | $756 | $746 | $580 |
| % Growth | 1,330.3% | 1.3% | 28.6% | – |
| Cost of Goods Sold | $512 | $0 | $0 | $0 |
| Gross Profit | $10,301 | $756 | $746 | $580 |
| % Margin | 95.3% | 100% | 100% | 100% |
| R&D Expenses | $25,533 | $16,339 | $16,577 | $17,355 |
| G&A Expenses | $24,310 | $13,495 | $14,002 | $12,306 |
| SG&A Expenses | $24,310 | $13,495 | $14,002 | $12,306 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $627 | $0 | $0 | $0 |
| Operating Expenses | $50,470 | $29,834 | $30,579 | $29,661 |
| Operating Income | -$40,169 | -$29,078 | -$29,833 | -$29,081 |
| % Margin | -371.5% | -3,846.3% | -3,999.1% | -5,014% |
| Other Income/Exp. Net | $556 | $445 | $146 | $57 |
| Pre-Tax Income | -$39,613 | -$28,633 | -$29,687 | -$29,024 |
| Tax Expense | -$6,336 | -$445 | -$146 | -$7,056 |
| Net Income | -$33,277 | -$28,188 | -$29,541 | -$21,968 |
| % Margin | -307.7% | -3,728.6% | -3,959.9% | -3,787.6% |
| EPS | -0.45 | -0.34 | -0.46 | -0.35 |
| % Growth | -32.4% | 26.1% | -31.4% | – |
| EPS Diluted | -0.45 | -0.34 | -0.46 | -0.35 |
| Weighted Avg Shares Out | 74,723 | 83,119 | 64,716 | 63,400 |
| Weighted Avg Shares Out Dil | 74,723 | 83,119 | 64,716 | 63,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,338 | $700 | $146 | $57 |
| Interest Expense | $782 | $255 | $146 | $0 |
| Depreciation & Amortization | $2,149 | $844 | $136 | $137 |
| EBITDA | -$38,020 | -$28,234 | -$29,405 | -$28,944 |
| % Margin | -351.6% | -3,734.7% | -3,941.7% | -4,990.3% |